Footnote:
†Including inhalations of selective β2-agonists, inhaled
glucocorticoids, fixed combinations of β2-agonists and glucocorticoids,
leukotriene receptor antagonists and xanthines.
‡Including chronic obstructive pulmonary disease, cystic fibrosis,
sarcoidosis, primary adrenocortical insufficiency, pneumonitis due to
external agents, inflammatory bowel disease, inflammatory
polyarthropathies, systemic connective tissue disorders, inflammatory
spondylopathies, and/or malignancy
Figure 2: Trends in the prevalence of oral corticosteroid use among
young adults with asthma in Denmark from 1999-2018, given as annual
prevalence stratified by A) OCS-exposure categories (low <5 mg
OCS/day and high ≥5 mg OCS/day per year), B) by sex, and C) by age
categories.